MEI Pharma Inc. (MEIP)

2.22
0.03 1.40
NASDAQ : Health Technology
Prev Close 2.19
Open 2.17
Day Low/High 2.16 / 2.28
52 Wk Low/High 1.48 / 3.26
Volume 86.00K
Avg Volume 125.30K
Exchange NASDAQ
Shares Outstanding 37.05M
Market Cap 78.18M
EPS 0.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

MEI Pharma Announces Study Of Clinical Stage Oral CDK Inhibitor Voruciclib Published In Nature Scientific Reports

MEI Pharma Announces Study Of Clinical Stage Oral CDK Inhibitor Voruciclib Published In Nature Scientific Reports

New Preclinical Studies Demonstrate Repression of MCL-1 and Sensitization to BCL-2 Inhibition in Diffuse Large B-Cell Lymphoma

MEI Pharma To Host Annual Meeting Of Stockholders

MEI Pharma To Host Annual Meeting Of Stockholders

Live Webcast from San Diego on November 30th

MEI Pharma To Present At Stifel 2017 Healthcare Conference

MEI Pharma To Present At Stifel 2017 Healthcare Conference

Live Webcast from New York on November 15th

MEI Pharma To Present At Cantor Fitzgerald Global Healthcare Conference

MEI Pharma To Present At Cantor Fitzgerald Global Healthcare Conference

Live Webcast from New York on September 26th

MEI Pharma Announces Exclusive License Agreement With Presage Biosciences For Voruciclib, An Oral, Selective CDK Inhibitor

MEI Pharma Announces Exclusive License Agreement With Presage Biosciences For Voruciclib, An Oral, Selective CDK Inhibitor

Clinical-Stage Asset in Validated Class of Drugs with Demonstrated Value

MEI Pharma To Present At Two Upcoming Investor Conferences

MEI Pharma To Present At Two Upcoming Investor Conferences

Live Webcasts from Boston on September 7th and New York on September 8th

Helsinn Group And MEI Pharma Announce First Patient Dosed In Pivotal Phase 3 Study Of Pracinostat And Azacitidine In Acute Myeloid Leukemia

Helsinn Group And MEI Pharma Announce First Patient Dosed In Pivotal Phase 3 Study Of Pracinostat And Azacitidine In Acute Myeloid Leukemia

Randomized, double-blind, placebo-controlled study to enroll up to 500 patients worldwide

Helsinn Group And MEI Pharma Announce First Patient Dosed In Phase 2 Dose-Optimization Study Of Pracinostat And Azacitidine In Myelodysplastic Syndrome

Two-stage study designed to evaluate tolerability and efficacy of pracinostat combined with azacitidine in patients with high and very high risk MDS

Interesting MEIP Call Options For December 16th

Interesting MEIP Call Options For December 16th

Investors in MEI Pharma Inc saw new options begin trading this week, for the December 16th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 136 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

MEI Pharma (MEIP) Stock Soars on Leukemia Treatment's Phase 2 Trial Results

MEI Pharma (MEIP) Stock Soars on Leukemia Treatment's Phase 2 Trial Results

MEI Pharma (MEIP) stock is surging in early-morning trading on Monday, after the oncology company announced positive results from its leukemia treatment's Phase II trial.

MEI Pharma (MEIP) Stock Rises Today Following Monday's Sharp Decline

MEI Pharma (MEIP) Stock Rises Today Following Monday's Sharp Decline

Shares of MEI Pharma (MEIP) were up in late morning trading Tuesday as investors swooped into the stock following its significant decline on Monday.

MEI Pharma (MEIP) Stock Plummets to 52-Week Low After Cancer Drug Trial Results

MEI Pharma (MEIP) Stock Plummets to 52-Week Low After Cancer Drug Trial Results

Shares of MEI Pharma (MEIP) plunged to a one-year low on Monday after the company announced its cancer drug Pracinostat failed to meet its main goal in a mid-stage trial.

First Week Of April 17th Options Trading For MEI Pharma (MEIP)

First Week Of April 17th Options Trading For MEI Pharma (MEIP)

Investors in MEI Pharma Inc saw new options become available this week, for the April 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MEIP options chain for the new April 17th contracts and identified one put and one call contract of particular interest.

4 Biotech Stocks Under $10 Triggering Breakouts: Amarin, Exelixis and More

4 Biotech Stocks Under $10 Triggering Breakouts: Amarin, Exelixis and More

Keep these under-$10 biotech stocks on your breakout trading radar.

5 Under-$10 Health Care Stocks Setting Up to Trade Higher

5 Under-$10 Health Care Stocks Setting Up to Trade Higher

These setups often produce monster moves higher in very short time frames.

Oversold Conditions For MEI Pharma (MEIP)

Oversold Conditions For MEI Pharma (MEIP)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

3 Under-$10 Health Care Stocks Triggering Breakout Trades

3 Under-$10 Health Care Stocks Triggering Breakout Trades

Keep these health care stocks under $10 on your breakout trading radar.

5 Breakout Stocks Under $10 Set to Soar

5 Breakout Stocks Under $10 Set to Soar

These under-$10 stocks look ready to break out and trade higher from current levels.

3 Biotech Stocks Under $10 to Trade for Breakouts

3 Biotech Stocks Under $10 to Trade for Breakouts

These under-$10 biotech stocks are within range of triggering breakout trades.

4 Biotech Stocks Under $10 to Watch for Breakout Trades

4 Biotech Stocks Under $10 to Watch for Breakout Trades

These under-$10 biotech stocks are within range of triggering breakout trades.

5 Stocks Under $10 Set to Soar

5 Stocks Under $10 Set to Soar

These under-$10 stocks are within range of triggering breakout trades.

Relative Strength Alert For MEI Pharma

Relative Strength Alert For MEI Pharma

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

3 Stocks Spiking on Big Volume

3 Stocks Spiking on Big Volume

Unusual volume can be a major signal that hedge funds and momentum traders are piling into a stock ahead of a catalyst.

Quant Rating on 12:32 PM EST 2/20/2018
TheStreet Quant Rating: D (Sell)